A Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for Metastatic Castration Resistant Prostate Cancer.

[tango65]

urotoday.com/conference-hig...

[cesanon]

" by targeting both the androgen receptor as well as androgen biosynthesis, the theory is that this may be more effective than targeting one pathway alone. Dr. Efstathiou’s study showed that this combination is safe and well tolerated for most patients, without significant drug-drug interactions. This study by Morris et al builds on that study by providing phase III randomized data comparing the combination vs enzalutamide alone."

"There was no significant difference in overall survival between the two groups (33.6 months vs and 32.7 months, two-sided p = 0.53). There was almost no difference in PSA decline either."

"The combination of abiraterone and enzalutamide for patients with mCRPC does not prolong survival compared with enzalutamide alone but does increase the toxicity of therapy. This combination approach should not be used for patients with mCRPC."

That's sort of nice to know.

What I would like to know is if you do the triple cocktail, can you use a lower dose to obtain the same effect. That to me is a very very important question that this study was not designed to answer.

It would seem to me that using the triple cocktail at a lower dose, might reduce side effects while generating the same results. Wouldn't that be nice?